Rifapentine (DL 473) | Bacterial Inhibitor

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	61379-65-5
Formula :	C₄₇H₆₄N₄O₁₂
M.W :	877.03
SMILES Code :	O=C1[C@](C)(OC2=C1C3=C(C(O)=C(NC4=O)C(/C=N/N5CCN(C6CCCC6)CC5)=C3O)C(O)=C2C)O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]([C@H](/C=C/C=C4/C)C)O)C)O)C)OC(C)=O)C)OC
Synonyms :	DL 473; Cyclopentylrifampicin; R 773
MDL No. :	MFCD00866806

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Murine macrophages (J774 A.1)	0, 5, 25, 50 μg/mL	24 hours	Evaluate the cytotoxicity of nanoparticles, results showed nanoparticles were non-toxic to macrophages with cell viability over 90%.	PMC7547843
Huh7 cells	0.5259 μM	48 hours	Evaluate the inhibitory effect of rifapentine on YFV, results showed that rifapentine significantly inhibited YFV infection	PMC8942558
A-498 cells	0.01 µg/mL	7 days	To evaluate the inhibitory effect of rifapentine on Coxiella burnetii, results showed that rifapentine exhibited significant inhibitory effects in A-498 cells with an MIC of 0.01 µg mL−1.	PMC11218529
THP-1 cells	≤0.01 µg/mL	7 days	To evaluate the inhibitory effect of rifapentine on Coxiella burnetii, results showed that rifapentine exhibited significant inhibitory effects in THP-1 cells with an MIC ≤0.01 µg mL−1.	PMC11218529
Mycobacterium tuberculosis	0.03 to 0.25 mg/L		Evaluate the antimicrobial efficacy of rifapentine against M. tuberculosis, showing it is 2 to 10 times more potent than Rifampin	PMC11782957

Mice	Tuberculosis model	Oral	15 mg/kg	Once weekly for 4 months	To evaluate the sterilizing activity of rifapentine in combination with moxifloxacin, results showed that once-weekly moxifloxacin plus rifapentine (15 mg/kg) was significantly more active than the predominantly twice-weekly Denver regimen	PMC2718441
BALB/c mice	Latent tuberculosis infection model	Gavage	15 mg/kg	Once weekly for 3 months	To evaluate the efficacy of rifapentine combined with isoniazid or moxifloxacin for the treatment of latent tuberculosis infection, showing that 3-month once-weekly rifapentine-containing regimens were as active as 6-9 months of daily isoniazid	PMC1853317
BALB/c mice	Murine model of tuberculosis	Oral	15 or 20 mg/kg	Twice weekly for 4, 5, or 6 months	To evaluate the bactericidal and sterilizing activities of rifapentine in tuberculosis treatment, results showed that twice-weekly rifapentine (15 or 20 mg/kg) regimens were more effective than standard daily therapy, achieving stable cure within 4 months.	PMC1862756
A129−/− mice	YFV infection model	Gavage	20 mg/kg/day	Once daily for 21 days	Evaluate the antiviral effect of rifapentine in YFV-infected mouse model, results showed that rifapentine significantly improved survival rate, alleviated clinical signs, and reduced virus load and injury in targeted organs	PMC8942558

{[proInfo.proName]}

CAS No.: 61379-65-5

{[proInfo.proName]}

CAS No.: 61379-65-5

Alternative Products

Product Details of Rifapentine

Safety of Rifapentine

Related Pathways of Rifapentine

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT02099240	Osteomyelitis	Early Phase 1	Recruiting	September 2019	United States, Kentucky ... More >> University of Louisville Recruiting Louisville, Kentucky, United States, 40202 Contact: Julio A Ramirez, MD 502-852-1148 jarami01@louisville.edu Contact: David Seligson, MD 502-852-0923 d0seli01@louisville.edu Sub-Investigator: Forest Arnold, DO Sub-Investigator: Timothy Wiemkwn, PhD Sub-Investigator: Robert Kelley, PhD Sub-Investigator: James Summersgill, PhD Sub-Investigator: Ruth Carrico, PhD Sub-Investigator: Julie Harting, PharmD Sub-Investigator: Paula Peyrani, MD Principal Investigator: David Seligson, MD Sub-Investigator: Craig Roberts, MD Principal Investigator: Julio Ramirez, MD Less <<
NCT03474198	Tuberculosis, Pulmonary	Phase 2 Phase 3	Recruiting	March 12, 2022	Philippines ... More >> De La Salle Health Sciences Institute Not yet recruiting Manila, Philippines Lung Center Philippines Recruiting Manila, Philippines Philippines Tuberculosis Society Incorporated (PTSI) Not yet recruiting Manila, Philippines Tropical Disease Foundation Not yet recruiting Manila, Philippines Singapore National University Hospital Not yet recruiting Singapore, Singapore Thailand King Chulalongkorn Memorial Hospital Not yet recruiting Bangkok, Thailand Less <<
NCT02689089	Tuberculosis	Phase 4	Recruiting	September 2019	Canada, Ontario ... More >> The Ottawa Hospital - General Campus Recruiting Ottawa, Ontario, Canada, K1H 8L6 Contact: Gonzalo Alvarez, MD 613-737-8899 galvarez@ottawahospital.on.ca Principal Investigator: Gonzalo Alvarez, MD, FRCPC Less <<
NCT00057122	HIV Infections ... More >> Tuberculosis Less <<	Phase 3	Completed	-	South Africa ... More >> Chris Hani Baragwanath Hospital Soweto, South Africa Less <<
NCT03089983	Opioid Dependence ... More >> Addiction HIV/AIDS Tuberculosis Hepatitis Less <<	Phase 4	Recruiting	April 2021	Malaysia ... More >> Kajang Prison Recruiting Kajang, Selangor, Malaysia Contact: Adeeba Kamarulzaman, MBBS Principal Investigator: Adeeba Kamarulzaman, MBBS Less <<
NCT02771249	Healthy Volunteers	Phase 1	Recruiting	December 31, 2019	United States, Maryland ... More >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY8664111010 prpl@cc.nih.gov Less <<
NCT00002192	Mycobacterium Avium-Intracellu... More >>lare Infection HIV Infections Less <<	Phase 2	Completed	-	United States, Virginia ... More >> Hampton Roads Med Specialists Hampton, Virginia, United States, 23666 Less <<
NCT01582711	Latent Tuberculosis Infection	Phase 3	Completed	-	United States, California ... More >> University of California, San Francisco San Francisco, California, United States, 94110 United States, Colorado Denver Public Health Department Denver, Colorado, United States, 80204 United States, District of Columbia Washington DC Veterans Affairs Medical Center Washington, District of Columbia, United States, 20422 United States, New York Columbia University College of Physicians and Surgeons and New York City Department of Health New York, New York, United States, 10032 United States, North Carolina Duke University Durham, North Carolina, United States, 27713 United States, Tennessee Vanderbilt University Medical Center and Nashville Metro Public Health Department Nashville, Tennessee, United States, 37232-0146 United States, Texas University of North Texas Health Science Center at Fort Worth Fort Worth, Texas, United States, 76104-4802 Audie L. Murphy VA Hospital San Antonio, Texas, United States, 78229-4404 South Texas - Department of State Health Services San Antonio, Texas, United States, 78229-4404 China TB and Chest service of Hong Kong Hong Kong, China South Africa Wits Health Consortium Soweto, South Africa Spain Agencia de Salut Publica - Barcelona, Spain and UNTHSC Barcelona, Spain, 08023 Less <<
NCT00023335	Pulmonary Tuberculosis	Phase 3	Completed	-	-
NCT02735590	Tuberculosis	Phase 2 Phase 3	Enrolling by invitation	May 30, 2019	South Africa ... More >> Centre for the Aids Programme of Research in South Africa (CAPRISA) Durban, KwaZulu-Natal, South Africa, 4013 Aurum Institute Klerksdorp, North West Province, South Africa, 2571 Aurum Institute Rustenburg, North West, South Africa, 0300 Stellenbosch Immunology Research Group Cape Town, Western Cape, South Africa, 7505 South African Tuberculosis Vaccine Initiative (SATVI) Worcester, Western Cape, South Africa, 6850 Less <<
NCT01404312	-		Completed	-	-
NCT03435146	Respiratory Tract Infections ... More >> HIV Infections Less <<	Phase 1 Phase 2	Recruiting	November 3, 2018	South Africa ... More >> The Aurum Institute: Tembisa Clinical Research Centre Recruiting Tembisa, Gauteng, South Africa, 1736 Contact: Modulakgotla Sebe, BCh, MB 27-87-1351645 msebe@auruminstitute.org Less <<
NCT02651259	Tuberculosis	Phase 1 Phase 2	Active, not recruiting	March 31, 2019	Haiti ... More >> Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS Port-au-Prince, Haiti, HT-6110 Kenya Kenya Medical Research Institute / Walter Reed Project Clinical Research Center, Kericho CRS Kericho, Kenya, 20200 Malawi Malawi CRS Lilongwe, Central Malawi, Malawi Thailand Siriraj Hospital ,Mahidol University NICHD CRS Bangkok, Bangkoknoi, Thailand, 10700 Zimbabwe Harare Family Care CRS Harare, Zimbabwe Less <<
NCT03266991	Compliance, Patient	Phase 4	Recruiting	January 2020	Denmark ... More >> Dept of Pulmonary Medicine Recruiting Aarhus, Denmark, 8000 Contact: Nina B Staerke, MD ninase@rm.dk Dept of Pulmonary Medicine Recruiting Esbjerg, Denmark, 6700 Contact: Torben Jensen, MD Less <<
NCT02208427	Latent Tuberculosis Infection	Phase 3	Unknown	December 2016	Taiwan ... More >> National Taiwan University Hospital Taipei, Taiwan, 100 Less <<
NCT01404312	Tuberculosis ... More >>HIV Infections Less <<	Phase 3	Completed	-	-
NCT00023426	Tuberculosis	Phase 2	Completed	-	-
NCT03510468	Healthy Volunteers	Phase 1	Recruiting	August 30, 2021	United States, Maryland ... More >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY8664111010 prpl@cc.nih.gov Less <<
NCT01162486	Tuberculosis ... More >>Tuberculosis, Pulmonary Less <<	Phase 1	Completed	-	United States, Maryland ... More >> Johns Hopkins University Baltimore, Maryland, United States, 21287 Less <<
NCT02641106	Tuberculosis ... More >>Latent Tuberculosis Infection Less <<	Not Applicable	Recruiting	December 2019	United States, California ... More >> San Diego County Health and Human Services Agency Recruiting San Diego, California, United States, 92110 Contact: Wilma J Wooten, M.D., M.P.H 619-515-6597 Wilma.Wooten@sdcounty.ca.gov Contact: Antonette Antonio, NP, RN 619-692-5718 Antonette.Antonio@sdcounty.ca.gov Less <<
NCT01574638	Tuberculosis	Phase 1	Completed	-	United States, California ... More >> UCSD Antiviral Research Center CRS San Diego, California, United States, 92103 United States, Maryland Johns Hopkins University CRS Baltimore, Maryland, United States, 21205 United States, North Carolina Chapel Hill CRS Chapel Hill, North Carolina, United States, 27599 United States, Tennessee Vanderbilt Therapeutics (VT) CRS Nashville, Tennessee, United States, 37204 Less <<
NCT01690403	Tuberculosis	Phase 1	Completed	-	United States, New York ... More >> Investigational Site Number 840001 Buffalo, New York, United States, 14202 Less <<
NCT00164450	Tuberculosis	Not Applicable	Completed	-	-
NCT00023452	-		Completed	-	-
NCT00023452	Tuberculosis	Phase 3	Completed	-	-
NCT02563327	Tuberculosis	Phase 3	Recruiting	March 2020	Uganda ... More >> Mulago Hospital Recruiting Kampala, Uganda Contact: Principal Investigator jlj@case.edu Less <<
NCT00023387	Tuberculosis	Not Applicable	Completed	-	-
NCT00460759	Mycobacterium Tuberculosis	Phase 1	Terminated	-	United States, Maryland ... More >> Johns Hopkins University Baltimore, Maryland, United States, 21287 Less <<
NCT02430259	Silicosis Tub... More >>erculosis Less <<	Phase 3	Unknown	December 2018	China, Zhejiang ... More >> Wenling No.1 People's Hospital, Zhejiang Recruiting Taizhou, Zhejiang, China, 317500 Contact: Xuefeng Liu, MD +86576-86206803 lhpxf@163.com Sub-Investigator: Xitian Huang, MD Less <<
NCT02980016	Tuberculosis ... More >>HIV Less <<	Phase 3	Active, not recruiting	September 2019	South Africa ... More >> The Aurum Institute NPC Johannesburg, Gauteng, South Africa, 2193 Less <<
NCT00728507	Tuberculosis	Phase 2	Terminated(Funding withdrawn)	-	Brazil ... More >> Centro de Referência Professor Hélio Fraga - ENSP - FIOCRUZ Curicica, Rio de Janeiro, Brazil, 22.780-192 Posto de Saude Albert Sabin Rio de Janeiro, RJ, Brazil, 20211-110 Hospital Universitario Clementio Fraga Filho Rio de Janeiro, Brazil Less <<
NCT02410772	Tuberculosis	Phase 3	Recruiting	December 2019	-
NCT00814671	Tuberculosis	Phase 2	Completed	-	South Africa ... More >> Universiy of Cape Town Lung Institute Cape Town, Western Cape, South Africa, 7937 Less <<
NCT02216331	Tuberculosis	Phase 1	Completed	-	United States, Nebraska ... More >> Celerion (MDS Pharma Services) Lincoln, Nebraska, United States, 68502 Less <<
NCT03730181	Latent Tuberculosis	Phase 1 Phase 2	Not yet recruiting	February 2022	-
NCT00809718	Healthy	Phase 1	Completed	-	United States, Texas ... More >> Audie L Murphy Veterans Administration Hospital San Antonio, Texas, United States, 78229 University of Texas Health Science Center San Antonio, Texas, United States, 78229 Less <<
NCT01043575	Smear Positive, Pan-sensitive,... More >> Pulmonary Tuberculosis Less <<	Phase 2	Completed	-	United States, Colorado ... More >> Denver Public Health Denver, Colorado, United States United States, Texas University of North Texas Denton, Texas, United States TBTC site 40 / South Texas Harlingen, Texas, United States Audie L. Murphy VA Medical Center San Antonio, Texas, United States South Africa University of KwaZulu Natal Durban, South Africa Uganda Uganda / Case Western Reserve Research Collaboration Kampala, Uganda Less <<
NCT03474029	Latent Tuberculosis	Phase 2 Phase 3	Not yet recruiting	December 2020	-
NCT00728507	-		Terminated(Funding withdrawn)	-	-
NCT00694629	Pulmonary Tuberculosis	Phase 2	Completed	-	-
NCT00814671	-		Completed	-	-

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed